News|Videos|November 10, 2026

Executive Conversations: Why Trade Strategy Has to Start Before Launch

Name: Executive Conversations: Has Commercial Trade Become Pharma's Strategic Engine?
Uploaded: 2026-11-10T18:23:40.926Z
Duration: PC5M9S
Description: In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

Author(s)Jon Hamrick, MBA, Bob Cochran, Rena Goins

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

In the first episode of Executive Conversations: The Future of Pharmaceutical Commercialization, presented by Pharmaceutical Commerce, three industry experts examine how commercial trade has become a strategic engine for bringing drugs to market. Host Jon Hamrick, partner at Curatio Advisors, is joined by Rena Goins, executive director, global trade at Regeneron Pharmaceuticals, and Bob Cochran, former senior director of trade relations at Incyte, who recently joined Curatio Advisors as a senior advisor.

Related to this article

November 6th, 2026

Bob Cochran: Direct-to-Patient Was a 'Watershed Moment' for Commercial Trade

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.

October 30th, 2026

Large Pharma vs. Emerging Biotech: Two Launch Playbooks

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

Blue Pills | © Alexander Limbach - stock.adobe.com 458202839

November 10th, 2026

The End of the Traditional Launch: How JCA, HTA Evolution and Pricing Pressures Are Driving Continuous Evidence Generation

Joint clinical assessment, shifting HTA demands and pricing pressure are making launch the start of continuous evidence generation.

packets of medical drug pills and tablets on a bright yellow background | ink drop - stock.adobe.com

November 5th, 2026

The System-Level View That Sound Market Access Decisions Are Missing

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

The integration of IoT in healthcare systems facilitates seamless data exchange between medical devices and electronic health records for improved patient care. | © lungkeemao - stock.adobe.com 1061704281

October 28th, 2026

As the Evidence Bar Rises, EVERSANA Acquires Estima Scientific

EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.

Ed Schoonveld is a Value & Access advisor for Schoonveld Advisory, LLC and author of The Price of Global Health

November 9th, 2026

When Drug Pricing Collides With Politics

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

November 6th, 2026

How CMS’ Final Negotiation Rule Treats New Drug Formulations

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

Pharmaceutical medicine sales growth chart with medical vials pills laboratory clinical development success healthcare industry finance market statistics data concepts. | © Eve - stock.adobe.com

November 5th, 2026

Report: 2026 Patient Support Awards Name Leaders in Large, Small Pharma

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.